Evidence map›Paper›PMID 36361609›Full record

ArticleInternational journal of molecular sciences2022

Shuterin Enhances the Cytotoxicity of the Natural Killer Leukemia Cell Line KHYG-1 by Increasing the Expression Levels of Granzyme B and IFN-γ through the MAPK and Ras/Raf Signaling Pathways.

Jen-Tsun Lin, Yi-Ching Chuang, Mu-Kuan Chen, Yu-Sheng Lo, Chia-Chieh Lin, Hsin-Yu Ho, Yen-Tze Liu, Ming-Ju Hsieh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jen-Tsun LinDepartment of Medicine, Division of Hematology and Oncology, Changhua Christian Hospital, Changhua 500, Taiwan.
Yi-Ching ChuangOral Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan.
Mu-Kuan ChenDepartment of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, Changhua 500, Taiwan.
Yu-Sheng LoOral Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan.
Chia-Chieh LinOral Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan.ORCID 0000-0002-2746-4054
Hsin-Yu HoOral Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan.ORCID 0000-0002-8496-1313
Yen-Tze LiuDepartment of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402, Taiwan.
Ming-Ju HsiehOral Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan.ORCID 0000-0001-9726-3234
Changhua Christian Hospital · TWNational Chung Hsing University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cell therapy is an emerging tool for cancer immunotherapy. NK cells are isolated from peripheral blood, and their number and activity are limited. Therefore, primary NK cells should be expanded substantially, and their proliferation and cytotoxicity must be enhanced. Shuterin is a phytochemical isolated from

Indexed as

LeukemiaMitogen-Activated Protein KinasesFlavonoidsGranzymesHumansInterferon-gammaK562 CellsKiller Cells, NaturalSignal TransductionFlavonoidsGranzymesInterferon-gammaMitogen-Activated Protein KinasesShuterinHNSCCINF-γMAPK pathwaynatural killer cellsshuterin

Identifiers

PMID36361609
PMCPMC9654641
OpenAlexW4307270541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.